Here's Why Merck (MRK) is a Strong Momentum Stock

Company Overview - Merck & Co. is based in Kenilworth, NJ, and has over six blockbuster products, with Keytruda being a PD-L1 inhibitor approved for various cancers, accounting for approximately 50% of its pharmaceutical sales [11] - Keytruda has significantly contributed to Merck's steady revenue growth in recent years, although there are concerns regarding the company's heavy reliance on this drug and the need for product diversification [11] Investment Ratings - Merck is currently rated as 3 (Hold) on the Zacks Rank, with a VGM Score of B [12] - The stock has a Momentum Style Score of A, and its shares have increased by 3.8% over the past four weeks [12] Earnings Estimates - For fiscal 2025, three analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate rising to $8.94 per share [12] - Merck has an average earnings surprise of +3.9%, indicating a positive trend in earnings performance [12] Investment Considerations - With a solid Zacks Rank and high Momentum and VGM Style Scores, Merck is recommended for investors' consideration [13]